ACE reagent is for use in the determination of angiotensin converting
enzyme (ACE) activity in serum or plasma at 340 nm.
Angiotensin converting enzyme (ACE, dipeptidyl carboxypeptidase) is
a glycoprotein peptidyldipeptide hydrolase that cleaves histidylleucine
dipeptide from angiotensin I, a relatively inactive decapeptide. The
latter is converted to the potent vasoconstrictor, angiotensin II. ACE
also inactivates bradykinin. Elevated levels of ACE activity occur in
serum of patients with active sarcoidosis, and occasionally in
premature infants with respiratory distress syndrome, in adults with
tuberculosis, Gaucher’s disease, leprosy, and in many other pathologic
conditions involving lung and liver diseases6,7.
CALIBRATION
It is recommended to use the ACE Calibrator (Ref. 1002225).
STORAGE AND STABILITY
All the components of the kit are stable until the expiration date on the
label when stored tightly closed at 2-8ºC.
After opening, the reagent is stable for 30 days when properly capped
immediately after each opening and stored at 2-8ºC protected from
light.
ADDITIONAL EQUIPMENT
- Spectrophotometer or colorimeter measuring at 340 nm.
- Thermostatic bath at 37º C ( 0.1ºC)
- Matched cuvettes 1.0 cm light path.
- General laboratory equipment.
SAMPLES
Fresh serum or plasma (lithium or sodium-heparin) promptly
separated from the red blood cells1.
Do not use: lipemic samples, haemolyzed samples or EDTA as an
anticoagulant as it inhibits the ACE activity 2,3,4,5,8
.
Stability: 7 days at 2-8ºC or 1 year at -20ºC.
INTERFERENCES
Unconjugated Bilirubin up to 13 mg/dL, conjugated Bilirubin up to 26 mg/dL,
haemglobin up to 100 mg/dL and lipids up to 200 mg/dL.
Captotril, and ACE inhibitory drug, used for the treatment of hypertension and
some types congestive heart failure, will inhibit ACE activity in serum or
plasma9,11
NOTES
1.SPINREACT has instruction sheets for several automatic analyzers.
BIBLIOGRAPHY
1. NCCLS Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture;
Approved
Standard – Fifth Edition (H3-A5). Wayne, PA: The National Clinical Laboratory Standards,
2003.
2. US Department of Labor, Occupational Safety and Health Administration. 29 CFR Part
1910.1030. Bloodborne Pathogens.
3. US Department of Health and Human Services. Biosafety in Microbiological and Biomedical
Laboratories, 5th ed. Washington, DC: US Government Printing Office, January2007.
4. World Health Organization. Laboratory Biosafety Manual, 3rd Ed.Geneva: World Health
Organization, 2004.
5. Sewell DL, Bove KE, Callihan DR, et al. Protection of Laboratory Workers from
Occupationally Acquired Infections; Approved Guideline - Third Edition (M29-A3). Wayne,
PA: Clinical and Laboratory Standards Institute, 2005.
6. Pesce, A.J., Kaplan, L.A.: “Methods in Clinical Chemistry”, Mosby Ed. (1987).
7. Burtis C.A., Ashwood E.R.: “Tietz Textbook of Clinical Chemistry”, W.B. Saunders Company
Ed. (3rd edition, 1999).
8. Guder W.G.: “The Quality of Diagnostic Sample”. Recommendations of the Working Group
on Preanalytical Quality of the German Society for Clinical Chemistry and the German
Society for Laboratory Medicine. (1st Edition - 2001).
9. Jakobs, D.S., Kasten, Jr., B.L., DeMott, W.R., Wolfson, W.L.: “Laboratory Test Handbook”,
Lexi-Comp and Williams & Wilkins Ed. (2nd Edition - 1990).
10. Silvia Camós, M. Jesús Cruz, Ferran Morell and Esther Solé: “Genetic-based reference
values for angiotensinconverting enzyme (ACE) according to I/D polymorphism in a Spanish
population sample”. Clin Chem Lab Med 2012;50(10):1749 -1753.
11. Beneteau B, Baudin B, Morgant G, Giboudeau J, Baumann FC. Automated kinetic assay of
angiotensin-converting enzyme in serum. Clin Chem 1986; 32: 884-6.
